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Abstract
Background: Since the application of MRI scanning to the diagnosis and treatment of multiple sclerosis, it has
been recognized that only a small fraction of lesions seen on MRI scans produce recognizable symptoms or
neurological findings. Because new lesions may occur without clinical detection, the recommendation has been
made that MRI scanning be performed on a routine scheduled basis, usually yearly, even in patients who are
clinically stable.
Methods: A retrospective chart review study was conducted on MS patients who had MRI scans of the central
nervous system between 2009 and 2012 at Providence Multiple Sclerosis Center. Inclusion criteria were patients
with relapsing MS who had been treated with interferon beta or glatiramer acetate for 6 months or longer. Information
on type, indication, and result of MRI and whether a change in disease modifying therapy occurred as a result of the
scan was collected.
Results: Of the 436 clinically stable patients who had routine MRI, 16.7 % of subjects had scans revealing new,
enlarged or active lesions, yet in only 4.4 % patients was there a change in therapy based upon MRI results. Subjects
who had MRI changes were found to be younger (50.15 vs 53.43, p = 0.02) but there was no significant difference in
other demographic or clinical characteristics when compared with the subjects who did not have MRI changes.
Thirty-six percent of patients with MRI changes did not change DMT due to patient request.
Conclusions: This study provides data on the likelihood of detecting MRI-documented disease activity, in patients
demonstrating longer term sustained clinical stability while receiving DMTs. These results may materially assist in the
decision whether or not to perform yearly MRI scanning of such patients. The potential clinical impact of the results of
routine MRI scanning must be weighed against the consideration of considerable expense of frequent MRI scanning,
and the yet unknown adverse impact of retained gadolinium in patients repeatedly receiving this contrast agent. The
long-term clinical impact of not changing DMTs in patients in whom MRI changes were observed will be addressed in
future studies of this cohort.
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Background
For patients with multiple sclerosis (MS), the advent of
MRI scanning has resulted in significant improvement in
the ability to accurately diagnose the disease [1–7],
and has provided important insights into disease activ-
ity [3, 8], prognosis [9–13], and response to thera-
peutic agents [8, 14, 15]. It has also been demonstrated
that MRI is a more sensitive indicator of on-going dis-
ease activity [2, 3] and burden of disease [2, 3] than
symptom reporting or clinical neurological examin-
ation. Accordingly, MRI scanning has assumed a major
role in routine management and therapeutic decision
making in patients with MS. It is the practice of many
clinicians to obtain periodic MRI scanning in clinically
stable patients, who are being treated with disease
modifying therapies (DMT), to detect the presence of
clinically silent disease activity. This practice has also
been endorsed on the basis of expert opinion [16], but
we are unaware of any data that support this practice,
particularly in clinically stable patients treated with
DMTs for more than 1 to 2 years. It had been our ex-
perience, in the community out-patient setting, that
the number of MRI scans showing significant change,
in clinically stable MS patients receiving DMT, were
few in number, leading us to question the value of per-
forming such scans on a routine basis and serving as
the rationale for the retrospective data analysis which
constitutes this report.
Methods
In this retrospective study, data from medical records of
patients who received their care at the Providence Mul-
tiple Sclerosis Center (PMSC) were collected and ana-
lyzed. All patients received comprehensive MS care from
PMSC neurologists who were experts in the diagnosis
and care of patients with MS. Each recorded clinic visit
included a complete interval symptom history, and a full
neurological examination, with standard clinical in-
formation obtained by the examining neurologist. All re-
cords were contained in a central electronic medical
record system. Chart review and data collection were
done by a registered nurse with extensive experience in
MS, using a standardized acquisition form and database.
Although it was not possible in the community setting
to assure that every patient was examined on the same
MRI scanner, all patients were studied using a 1.5 or 3.0
tesla MRI scanner, utilizing a standardized MS protocol,
with 5 mm contiguous gap-free slices of the brain. All
scans were interpreted by neuroradiologists with extensive
experience in diagnostic imaging for MS, and also by the
MS neurologist caring for the patient. Brain MRI se-
quences included T1 and T2 weighted axial, FLAIR axial
and sagittal, diffusion weighted axial, and gadolinium-
enhanced axial views in each patient. Spinal sequences
included T1, T2, STIR, FRFSE and T1 gadolinium-
enhanced sequences in 4 mm sagittal and 3 mm axial
planes. There was at least a 5 min delay following comple-
tion of gadolinium infusion before obtaining the T1
weighted enhanced images.
Patients were included in the chart review if they were
18 years or older, had been diagnosed with MS and had
been receiving interferon beta (IFN-B) or glatiramer
acetate (GA) at PMSC between January 1, 2009 and
December 31, 2012. The study was approved by Provi-
dence Institutional Review Board. The IRB granted waiver
of consent because the study utilized existing records that
had been collected for non-research purposes and the data
had been de-identified before they were used for the ana-
lysis of this study.
Of the 740 patients eligible for chart review, 223 were
excluded from the analysis for the following reasons:
progressive forms of MS [16] (n = 30), participation in
any investigational drug trial (n = 16), had not received
IFN-B or GA for at least 6 months (n = 21), did not have
any central nervous system (CNS) MRI performed be-
tween 2009 and 2012 (n = 47), did not have two or
more office visits during the 4 year observation period
(n = 17), were concurrently receiving more than one
MS DMT, excluding those who received intravenous
corticosteroids for a relapse, (n = 10), had a co-existing
neurological disorder (n = 4), did not have a definite
diagnosis of MS by McDonald criteria (n = 8), or had
received IFN-B or GA between 2009 and 2012 but were
being treated with natalizumab at the time of the MRI
of interest (n = 68). Another two patients were removed
from the study due to poor compliance of their DMT
determined by the treating physician. The final sample
consisted of 517 patients with relapsing MS, including
those with a single clinical event (Clinically Isolated
Syndrome or CIS). The disposition of the study cohort
is presented in Fig. 1.
All MRI results obtained between January 1, 2009 and
December 31, 2012 were reviewed. Scans were categorized
into the following: “routine” if they were not performed in
response to new or altered symptoms reported by the pa-
tient or changes observed in the neurological examination,
or “clinically indicated” if they were obtained in response
to changes in neurological signs and/or symptoms. Scans
were also categorized as brain, cervical or thoracic spinal
cord. Additional data obtained included patient demo-
graphics, time since diagnosis of MS, duration of IFN-B or
GA use, relapse history, date, reason and type of MRI per-
formed, MRI results, DMT change and reason for DMT
change following scan results.
Demographic and clinical characteristics of patients
were expressed as number, mean and standard deviation
or percentage, depending on data type. The number and
proportion of “routine” MRI scans that revealed changes
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or resulted in a switch in DMT were calculated overall
and by MRI scan and lesion type. Lesions were charac-
terized as changed if there was reported enlargement of
pre-existing lesions, new lesions or gadolinium enhan-
cing lesions. T-tests or non-parametric tests, depending
on data distribution, and chi-square tests were used to
analyze differences between patients with and without
MRI changes on routine scans. P-values less than 0.05
were considered significant. Statistical analyses were per-
formed utilizing SPSS version 22.0.
Results
The study cohort (n = 517) had a mean age of 51.2
(±11.7) years (range 20–83) and was predominantly female
(82 %). Mean duration of disease was 12.0 (±7.5) years
(range 2–46). At baseline, 94.2 % of patients (n = 487) had
RRMS and 5.8 % (n = 30) had CIS. The distribution of
MS therapies were: 77.8 % (n = 402) on IFN-B 1a,
20.8 % (n = 108) on GA, and 1.4 % (n = 7) on IFN-B 1b.
The mean duration of therapy on their current DMT
was 5.73 (±3.75) years (range 0.6–20). The demo-
graphic and clinical characteristics of patients in the
study cohort who had routine MRI are shown in
Table 1.
Mean and median observation times included for this
study were 2.65 and 3.17 years, respectively. An average of
0.85 MRI was performed per patient per year (on average
an MRI every 14.1 months). For the 517 patients included
in the study, a total of 1,347 scans were obtained: 64 %
brain (n = 871), 25 % cervical spine (n = 335) and 11 %
thoracic-lumbar spine (n = 141). Sixty-six percent of the
scans (n = 886) were ordered in 436 patients who had
been clinically stable (“routine”). Of the 436 patients for
whom “routine” MRI results were reviewed, changes were
observed on 73 patients (16.7 %). Of these, 94.5 % (n = 69)
Table 1 Patient characteristics and demographics
Description Mean (SD) or % Number
Age, mean years (SD) 51.2 (11.7) 517
Female, % 82 424
MS Pattern, %
Relapsing Remitting MS 94.2 % 487
Clinically Isolated Syndrome 5.8 % 30
Duration of Disease, mean years (SD) 12 (7.5) 363








IFNB 1a 77.8 402
IFNB 1b 1.4 7
GA 20.8 108
Abbreviations: DMT disease modifying therapy, IFNB interferon beta, GA
glatiramer acetate
Fig. 1 Disposition of the study population
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had new lesions, 24.7 % (n = 18) had enhancing lesions,
and 16.4 % (n = 12) had enlarged lesions. However, only
26.0 % (n = 19) of these patients subsequently changed
DMT due to the MRI results, representing only 4.4 % of
the 436 patients who had “routine” MRIs. The 54 patients
did not change DMT after routine MRI revealed changes
for the following reasons: 26 by patient request, 10 by
physicians’ recommendation, 1 for an insurance issue, 8
due to differing conclusions of the MRI results between
the MS neurologist and the neuroradiologist. In addition,
3 patients not initially excluded, were considered in-
sufficiently adherent in their use of MS medication. An-
other 6 patients were lost to follow up after their last
MRI scan; therefore, we could not confirm DMT
change.
There were a total of 54 new and/or enhancing lesions
observed in the 62 scans obtained in the 54 patients
who did not change DMT. The locations of the 54 le-
sions are presented in Table 2. Of these lesions, 5 were
enhancing, with the largest being a non-enhancing lesion
9 mm in its greatest diameter (a subcortical non-
enhancing white matter lesion in a patient electing not
to change medication) and all other lesions being 5 mm
or less in their greatest diameter. Of the 10 patients in
whom physicians elected not to change medication
based upon MRI changes, 14 new lesions were detected,
8 of which were 4–5 mm in their greatest diameter and
6 of which were 2–3 mm in diameter. However, none
were enhancing, enlarging, or in the spinal cord or brain
stem.
The patients whose routine MRI revealed changes were
younger (50.15 vs 53.43 years old, p = 0.02) than those
with stable MRI. No significant differences were found in
disease duration (p = 0.42), DMT used (p = 0.58), duration
of medication use (p = 0.53), disease pattern (p = 0.17),
gender (p = 0.93), or type of health insurance (p = 0.46) be-
tween the two groups (Table 3).
Discussion
Studies have demonstrated that the use of MRI scanning
increases the sensitivity and specificity of diagnosis in
MS [1–7, 17]. MRI is now an important element in
widely utilized MS diagnostic criteria [17], as well as a
measure of efficacy in clinical trials [13, 14, 17–27]. Fur-
thermore, use of MRI in patients treated with IFN-B,
particularly during the first 1–2 years of initiating medi-
cation, may be a predictor of prognosis and response to
therapy [7–11]. Although yearly use of MRI scans in pa-
tients with relapsing MS is recommended by expert
opinion [2, 6], we are unaware of any data that supports
the routine yearly use of MRI scanning in clinically
stable patients receiving DMTs over the longer term. In
our cohort of clinically stable patients, the mean interval
between scans was 14.1 months, and the mean duration
of their current therapy was 5.73 years. New, enlarged
and/or gadolinium-enhancing lesions were detected in
16.7 % of these clinically stable patients. Even if one ex-
cludes the small number of cases in which the neurologist
did not agree with the official neuroradiologic diagnosis
(n = 8), or were retrospectively excluded because of insuf-
ficient medication compliance (n = 3), 14.4 % of the pa-
tients demonstrated MRI evidence of disease activity.
With exception of patient age, there were no factors iden-
tified which were significantly associated with the risk of a
subject exhibiting worsening on MRI in the absence of
change in symptoms or findings.
The range of available, meaningful medication changes
were limited during the time span of this study, and in
the 10 cases in which the neurologist chose not to
change DMT, the limited number of alternative choices
and concerns for patient safety may have influenced this
decision. Over the past several years “no evidence of dis-
ease activity” (NEDA) has emerged as the sought after
Table 2 Localization and frequency of lesions in patients with
MRI findings but did not change DMT
Location No. (total n = 54)
Frontoparietal subcortical or deep white matter 26
Frontal juxtacortical 1







Cervical spinal cord 4
Table 3 Comparisons of demographic and clinical characteristics






Age, years 50.15 53.43 0.023
Female, % 82.4 82 0.929
MS Pattern, % 0.172
Relapsing Remitting MS 97.3 93.1
Clinically Isolated Syndrome 2.7 6.9
Duration of Disease, years 11.39 12.17 0.424




Yeas of Current DMT Use, mean 5.55 6.06 0.53
Abbreviations: DMT disease modifying therapy, IFNB interferon beta,
GA glatiramer acetate
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standard for therapeutic outcome in clinical trials as well
as in clinical practice, and has become a potentially
more achievable outcome as a consequence of the in-
creasing number of new, more selectively targeted DMTs
that have become available [28]. Although we do not yet
know whether evidence of subclinical disease activity in
longer term DMT-treated patients is of comparable
prognostic significance to that observed in patients who
had shorter treatment durations [7–12], it would be pru-
dent to assume that risk of future clinical disease activity
and disability worsening is significant and thus prompt
recommendation for change in DMT. MRI scanning
more often than yearly might reveal MRI lesions missed
by yearly intervals. Although a greater scanning fre-
quency might detect short-lived gadolinium enhancing
lesions, this probably would have little to no significant
impact on the number of new or enlarged lesions seen
on T2-weighted images with yearly scanning.
The strengths of our study include the large cohort
size, the community base of patients, and elimination of
the potential case selection bias inherent in most pro-
spective controlled clinical trials. In addition, our patient
cohort had been closely followed, in one treatment cen-
ter with expert MS neurologists administering standard-
ized neurological examination and MRI scans and
complete clinical and treatment history of the subjects
available for review.
Shortcomings of this study include its retrospective
design and the inability to insure that every subject was
studied on the same MRI scanner longitudinally. There
was also an imbalance in the percentage of patients re-
ceiving IFN-B vs GA. It is important to note that the re-
sults of this study cannot be extended to include
medications other than IFN-B and GA, and are not rele-
vant to patients not receiving DMT’s, in whom it has
been demonstrated that on-going disease activity occurs
in the absence of changes in clinically apparent disease
activity [3].
Although contiguous MRI sections were without gaps,
the 3–5 mm slice thickness may have resulted in missing
some small lesions, and lesion size would have been
better characterized if more precise volumetric measure-
ment of each lesion could have been obtained with
thinner slices. Although this represents a technical weak-
ness of this study that may have led to under-estimation
of disease activity in this population, this work does repre-
sent the real world MS clinical center setting, in which
most MS patients are cared for, and in which most clinical
management decisions regarding MS patient care must be
made. We do not believe that these shortcomings signifi-
cantly affect the validity of our observations, and although
the long term clinical impact of subclinical MRI activity is
not known, the large percentage (14.4–16.7 %) of patients
in this study demonstrating subclinical disease activity
supports routine scheduled MRI scanning. While our
study reflects the experience of one MS Center, the results
should prompt other clinicians to employ yearly MRI
scanning in their stable patient population.
Conclusions
This study demonstrated a high likelihood, up to 16.7 %,
of detecting disease activity in clinically stable MS patients
being treated with IFN-B or GA, in a community-based
cohort in which routine MRI scanning was performed on
a yearly basis. This level of clinically undetected disease
activity supports the practice of at least yearly routine
MRI scanning in clinically stable patients, to strengthen
efforts to optimize use of DMTs and increase the number
of patients achieving NEDA. These recommendations
should be weighed against the considerable expense of
frequent MRI scanning and the as yet unknown adverse
impact of retained gadolinium in patients repeatedly re-
ceiving this contrast agent. The long-term clinical impact
of not changing DMTs in patients in whom MRI changes
were observed will be addressed in future studies of this
cohort.
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